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Abstract: Human milk (HM) is a unique nourishment believed to contain biological factors
contributing to both short and long-term benefits. Considering that a mother’s own milk is often
considered the first choice for nutrition of neonates, an aspect of increased interest is the possible
effect of diabetes on the mammary gland and therefore on breast milk composition. This article aims
to review the published literature on this topic, and to offer additional insights on the role of this
disease on the composition of HM. This review was performed by searching the MEDLINE, EMBASE,
CINHAL and Cochrane Library databases. A total of 50 articles were selected, focused specifically on
one of the two types of diabetes: gestational diabetes mellitus (21 studies) and insulin-dependent
diabetes mellitus (8 studies). Overall, the findings from the literature suggest that diabetes can alter
the composition of HM. Nevertheless, the studies in this field are scarce, and the related protocols
present some limitations, e.g., evaluating the variability of just a few specific milk biochemical markers
in association with this syndrome.
Keywords: human milk; breastfeeding; gestational diabetes mellitus; insulin-dependent diabetes
mellitus; preterm newborn
1. Introduction
Human milk (HM) is a specie-specific biological dynamic fluid and significantly varies from one
woman to another. HM constantly changes during lactation to adapt to the physiological needs of the
developing infant [1] and this also comes about because of the gradual maturation of the mammary
gland, which depends on the placenta and thus on the progress of the pregnancy. The policy statement
of the American Academy of Pediatrics (AAP) regarding breastfeeding affirms that “Breastfeeding and
human milk are the normative standards for infant feeding and nutrition” [1]. In addition, the AAP
highlights that the mother’s own milk, fortified appropriately, should be the primary diet also for the
preterm newborns. These recommendations are due also to the fact that breastfeeding has been shown
to have beneficial effects on short- and long-term maternal and infant health outcomes [1–3].
It has been proposed that nutrition signals during the early postnatal period may
influence metabolic developmental pathways and induce permanent changes to metabolic disease
susceptibility [4,5]. In support of these hypotheses, studies have reported that human milk (HM) has
a protective effect on obesity and type 2 diabetes later in life [5,6]. Benefits of HM are mediated by
specific bioactive substances that transiently regulate tissue activities while the neonate’s systems
mature [7,8]. Biological active components, such as hormones, immunoglobulins, lysozyme, lactoferrin,
saccharides, nucleotides growth factors and enzymes antioxidants, are involved in immunological
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and metabolic regulation, and it has been hypothesized that they mediate growth and development in
infancy [9,10]. Furthermore, HM is a “dynamic” system: the composition changes and is influenced
by several conditions, such as term-preterm delivery, maternal diet, metabolic abnormalities and
pathologies [11].
Diabetes is a pathological condition of the lactating mother that may preexist (type 2 diabetes, type
1 diabetes or insulin-dependent diabetes mellitus (IDDM)) or appear during the pregnancy. The latter
case is identified as gestational diabetes mellitus (GDM) and is a common pregnancy complication.
It is defined as a carbohydrate intolerance of variable severity, with onset or first recognition during
pregnancy. Diabetes is associated with several short- and long-term complications for the mother and
the newborns and it is known that this pathology can delay the onset of lactogenesis II and affect
the composition of the human milk [12]. Bearing in mind the important impact of the HM on the
development of the newborns and the potential effects of the diabetes on the composition of the milk,
several studies were conducted to evaluate the variability of milk biochemical markers in association
with this pathology.
A comprehensive review and comparison of the related data on the effects of diabetes conditions
on the specific composition of HM of the lactating mother is, to the best of the authors’ knowledge, not
available in the literature. Our aim is to assess the current knowledge on the interactions between
diabetes in pregnancy and the composition of the HM in order to better understand the potential effects
of this pathology on the nutrition and development of newborns.
2. Materials and Methods
The literature review was performed by conducting electronic searches of MEDLINE (via PubMed
and PubMed Central), EMBASE, CINHAL and the Cochrane Library. The electronic search used the
following keywords and MeSH terms: (i) human milk AND (gestational diabetes OR gestational
diabetes mellitus OR insulin-dependent diabetes mellitus OR type 2 diabetes); (ii) breastfeeding
composition AND (gestational diabetes OR gestational diabetes mellitus OR insulin-dependent
diabetes mellitus OR type 2 diabetes); (iii) breast milk AND (gestational diabetes OR gestational
diabetes mellitus OR insulin-dependent diabetes mellitus OR type 2 diabetes); (iv) preterm breast milk
AND (gestational diabetes OR gestational diabetes mellitus OR insulin-dependent diabetes mellitus
OR type 2 diabetes); (v) human milk composition AND (gestational diabetes OR gestational diabetes
mellitus OR insulin-dependent diabetes mellitus OR type 2 diabetes); (vi) breast milk composition
AND (gestational diabetes OR gestational diabetes mellitus OR insulin-dependent diabetes mellitus
OR type 2 diabetes).
No publication date limits were set. For a complete comprehension of the studies, the inclusion
criteria were: (i) primary (original) research published in a peer-reviewed journal in the English
language and (ii) full text available. For the same reason, case reports, commentaries, letters to the
editor, and reviews were excluded. Articles including data related to animal milk were also excluded.
Literature searches were performed in the period between 1 June 2019 and 1 November 2019.
3. Results
A total of 50 articles were found from a combination of the searches, but only 29 fulfilled the
inclusion criteria, as shown in the flow diagram below, Figure 1.
The selected literature studies were focused specifically on one of two types of diabetes: GDM
or IDDM. In line with this finding, we evaluated the studies separately, based on the diabetes type.
Since type 2 diabetes was only referenced in a single article and compared to GDM, it is not discussed
separately in our review.
The available literature data on GDM and HM are summarized in Tables 1 and 2, whereas data on
IDDM and HM are summarized in Tables 3 and 4.
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3.1. Gestational Diabetes Mellitus—GDM
We found 21 articles focused on gestational diabetes mellitus; the related information is
summarized in Tables 1 and 2.
Table 1. Materials and methods of the different studies included in the survey regarding gestational
diabetes mellitus (GDM) and human milk (HM). (Col: colostrum; Trans: Transitional milk; Mat:
Mature milk).
Study GDMTreatments Sample Time
Gestational
Age
Parameters
Analyzed
Sample Size (GDM
vs. Control Women)
[13] Diet
Col: 0–5 days
Trans: 6–14 days
Mat: >14 days
Preterm Macronutrients andenergy 27 vs. 183
[14]
Diet
Other
medications
Col: 72 h
Trans: 7 days
Mat: 14 days
Term Macronutrientsand energy 31 vs. 31
[15] Not evaluated Col: 2–4 days Term
Total proteins
Total lipids
Triglycerides
cholesterol
Lactose
Glucose
Calcium
Inorganic
phosphorus
Electrolytes
IgA
20 vs. 20
[16] Diet Col: 7 daysMat: 3 months Term
Adiponectin
Insulin 170 women
[17] DietInsulin
Col: 3 days
Mat: 42–90 days Term
Leptin
insulin
ghrelin
adiponectin
48 vs. 48
[18] Not evaluated Col: 24–48 hMat: 30 days N/A
Leptin
adiponectin
insulin
12 vs. 21
[19] Diet Col/Mat Term
Apelin
nefastin-1
ghrelin
10 vs. 10
[20] Diet Col: 2 daysMat: 15 days Term Ghrelin
14 vs. 12 vs. 3
Pre-GDM
[21] Not evaluated Col: 72 hMat: 6 weeks Term Irisin a SREBP-1c 33 vs. 33
[22] Not evaluated
Col: –5 days
Trans: 6–15 days
Mat: >15 days
Term
Irisin
Adropin
Copeptin
15 vs. 15
[23] Not evaluated
Col: 1 day
Trans: 7 days
Mat: 20 days
Term
Preptin
Salusin
Hepcidin
12 vs. 12
[24] Not evaluated Trans: 2 weeks Term
Lactoferrin
sIgA
oligosaccharides
8 vs. 16
[25] Diet
Col: 1–5 days
Trans: 7–10 days
Mat: 15–17 days
Term ChemerinDermcidin 26 vs. 27
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Table 1. Cont.
Study GDMTreatments Sample Time
Gestational
Age
Parameters
Analyzed
Sample Size (GDM
vs. Control Women)
[26] Insulin
Col: First day of
secretion and 2
days later
Term
Neutrophil
gelatinase-associated
lipocalin (NGAL)
Complex
NGAL/matrix
metalloproteinase-9
(MMP-9)
13 vs. 22
[27] DietInsulin
Col: within 4 days
Mat: 6 weeks Term Free amino acids 21 vs. 47
[28]
Diet
Insulin
Other
medications
Col: 1–3 days Term Proteome 6 vs. 12
[29] Not evaluated Col:1–5 days Term Fatty acidcomposition 29 vs. 34
[30] Dietinsulin Col: 1–3 day Term Sodium 17 vs. 116
[31] Not evaluated Col: 1 day TermPreterm Alpha-Tocopherol 20 vs. 31
[32] Not evaluated Col: 3–5 daysMat: 3 months Term MicroRNAs 19 vs. 47
[33] Not evaluated
Col: 1–3 days
Trans: 7–10 days
Mat: 4 weeks
Term Metabolome 90 vs. 94
Table 2. Results of the different studies included in the survey regarding GDM and HM.
Components Effects Reference
Energy content IncreaseDecrease
Col/Trans/Mat: [13]
Mat: [14]
Total protein content
No differences Col: [13–15]
Trans/mat: [14]
Decrease Trans/mat: [13]
Insulin
No differences Col: [16,18]Mat: [18]
Increase Col: [17]Mat: [16,17]
Adiponectin No differencesDecrease
Col/Mat: [16,18]
Col/Mat: [17]
Ghrelin No differencesDecrease
Trans: [17,19,20]
Col/Mat: [17,19,20]
Irisin Decrease
Col/Trans: [21,22]
Mat: [21]
No Differences Mat: [22]
Apelins and Nesfatin-1 Increase Col/Mat: [19]
Copeptin, adropin No Differences Col/Trans/Mat: [22]
Preptin IncreaseNo Differences
Col: [23]
Trans/Mat: [23]
Salusin-alpha/-beta DecreaseNo Differences
Col: [23]
Trans/Mat: [23]
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Table 2. Cont.
Components Effects Reference
Pro-hepcidin and hepcidin-25 IncreaseNo Differences
Col/Trans: [23]
Mat: [23]
SREBP1-c No Differences Col/Mat: [21]
IgA No DifferencesDecrease
Col: [15]
Trans: [24]
Lactoferrin Increase Trans: [24]
Chemerin and Dermicin Increase Col/Trans/Mat: [21]
NGAL
NGAL/MMP-9
No differences
Increase
Col: [26]
Col: [26]
Total saccharides content
No differences Col/Trans: [13,14]Mat: [13]
Decrease Mat: [14]
Glucose No differences Col: [15]
Lactose Decrease Col: [15]
Oligosaccharides No differences Trans: [24]
Total lipid content No differences
Col: [13,14]
Trans: [13,14]
Mat: [13]
Decrease Col: [15]Mat: [14]
Cholesterols No differences Col: [15]
triglycerides No differences Col: [15]
Fatty acid composition
-γ-linolenic, eicosatrienoic,
arachidonic, and docosatetraenoic
No differences
Increase
Col: [29]
Col: [29]
Potassium, Phosphorus and
Calcium No differences Col: [15]
Sodium No differences Col: [15,30]
Vitamin E No differences Col: [31]
Micro RNA No differences Col/Mat: [32]
3.1.1. Energy
The energy content of the HM of women diagnosed with GDM was evaluated in two studies,
with opposite results: one study showed higher energy content in all phases of lactation with respect
to healthy mothers, whereas the other study reported a lower energy content in the mature milk
of pathological mothers. Both studies used an MIRIS scanner for the analyses of the samples; the
differences only consisted of the methods used to collect and store HM samples [13,14].
3.1.2. Protein Content
The total protein content was investigated in three studies, with similar results concerning the
colostrum: no significant differences were found with respect to the control group. Nonetheless,
data reported in relation to transitional and mature milk were conflicting: Dritsaku et al. found a
reduction in concentration of both types of HM, whereas the results of Saphira et al. showed no
differences [13–15].
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3.1.3. Hormones
Insulin was evaluated in several studies, both in colostrum and mature milk. Ley et al. used an
electrochemiluminescence immunoassay and showed that insulin concentrations in early milk were
higher than those in mature milk. They found that maternal prenatal metabolic measures, including
higher pre-gravid body mass index (BMI), gravid hyperglycemia, insulin resistance, lower insulin
sensitivity and higher serum adiponectin were associated with higher insulin concentrations in mature
milk, whereas these factors were not associated with altered insulin concentrations in early milk [16].
Another two studies analyzed the HM samples with an ELISA test, but found opposite results. Yu et al.
showed an increase of insulin levels, not only in mature milk, but also in colostrum in women with
GDM, especially in those receiving insulin injections [17]. Nunes et al. did not find differences in both
types of milk [18].
Adiponectin levels showed similar conflicting results: two studies demonstrated that GDM was
not associated with variations of adiponectin levels in HM, whereas Yu et al. observed that women
with GDM had lower concentrations of adiponectin in colostrum on day 3 and mature milk on day 90,
but no differences on day 42 [16–18].
There is agreement in the Ghrelin data: Ghrelin levels were found to be lower in colostrum and
mature milk, but no differences were observed in transitional milk [17,19,20].
Irisin concentrations, analyzed in two studies, were accordingly found to be low in GDM subjects
in the colostrum and transitional milk [21,22]. In mature milk, Fatima et al. observed a reduction in
concentrations, not confirmed by Aydin et al. [21,22]. In addition, the study by Aydin et al. found
Irisin levels to increase from the colostrum to transitional and mature milk in both normal glucose
tolerant and GDM patients [22].
Several other biologically active components with hormonal activity are evaluated in one study
by the same group of researchers. The study considered only mothers who did not take insulin, with
no complications during pregnancy and who had full term deliveries. Instead, the concentrations of
Apelins and Nesfatin-1 in HM in GDM lactating women was lower than in the control samples and
the concentrations of Apelins and Nesfatin-1 were higher in the mature milk than in colostrum [19].
Copeptin, adropin and polypeptide are hormones implicated in energy homeostasis and diabetes [22].
The authors found that the copeptin concentration was significantly higher in colostrum than transitional
milk, and the highest concentration was in mature milk from women with or without GDM [22].
Conversely, the adropin concentrations were significantly lower in the colostrum than in transitional
milk, and the lowest concentration was in mature milk from women with or without GDM [22].
Preptin, salusin-alpha and -beta and pro-hepcidin and hepcidin-25 concentrations were evaluated
in all phases of breastfeeding [23]. The data demonstrated that women with GDM had significantly
higher colostrum preptin and colostrum/transitional pro-hepcidin and hepcidin-25 concentrations
than healthy lactating women. Salusin-alpha and -beta levels were lower in colostrum of women with
GDM [23]. SREBP1-c profile showed a level reduced from a very low value to an undetectable range in
colostrum and mature breast milk, respectively [21].
3.1.4. Anti-Infective Proteins
IgA content was evaluated in the colostrum in one study and in transitional milk in another
study [15,24]. No differences were observed in the colostrum, while a decrease of total protein and
glycosylation of sIgA was found in transitional milk. Lactoferrin was analyzed only by Smilowitz et
al. in transitional milk, observing an increased glycosylation of this protein. The results suggest that
maternal glucose dysregulation during pregnancy has lasting consequences that may influence the
innate immune protective functions of HM [24].
Ustebay et al. analyzed Chemerin and Dermicin in all phases of lactation and found that these are
significantly increased by GDM; moreover, the highest amount was found in the colostrum and the
lowest in mature milk [25].
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Metallinou et al. evaluated the levels of Neutrophil gelatinase-associated lipocalin (NGAL) and its
complex with matrix metalloproteinase-9 (MMP-9) in the colostrum and found that the mean complex
concentration was significantly higher in diabetic pregnancies in comparison to normal ones [26].
3.1.5. Proteomics Profile
The proteomics profile was assessed in two studies, using different techniques (high-performance
liquid chromatography or high-sensitivity, label-free, semiquantitative mass spectrometry) [27,28].
Klein et al. evaluated the content of 11 free amino acids (FAAs) in the colostrum and mature milk
in women with or without GDM. The authors found that the total amount of FAA increased from
colostrum to mature milk in all patients. Moreover, the total amount did not significantly differ between
groups, as well as the concentrations of each individual amino acid [27].
Grapov et al. determined the proteomic profiling only of colostrum. A total of 601 proteins
were identified, of which 260 were quantified. Orthogonal partial least-squares discriminant analysis
identified 27 proteins that best predict GDM. The power law global error model, corrected for multiple
testing, was used to confirm that 10 of the 27 proteins were also statistically significantly different
between women with GDM and those without GDM. The identified changes in protein expression
suggest that diabetes mellitus during pregnancy has consequences on human colostral proteins
involved in immunity and nutrition [28].
3.1.6. Saccharides
The total saccharides content was evaluated in two studies. Both found no differences between
groups in the colostrum and transitional milk, although different results regarding mature milk were
reported: Saphira et al. observed a lower concentration in GDM, while Dritsaku et al. did not find
differences [13,14].
Lactose and glucose were analyzed only in one study and only in the colostrum; lactose was found
to be lower in GDM women, whereas glucose seemed unaltered by this pathological condition [15].
In conclusion, a single study evaluated the oligosaccharides in transitional milk and no differences
between groups were found in the results [24].
3.1.7. Lipids
The total lipid content was evaluated in three studies with discordant results. Kaushik et al.
analyzed only the colostrum and found a reduction in total content in the GDM group [15]. On the
other hand, Dritsaku et al. and Saphira et al. did not show any difference in concentration. Similarly,
regarding mature milk, Saphira et al. found a reduction, but Dritsaku et al. did not observe a
significant difference. Regarding transitional milk, all studies agreed and found no differences between
groups [13,14].
Kaushik et al. also analyzed the concentration of triglycerides and cholesterols in colostrum; in
this case no differences in content in GDM HM were identified [15].
Azulay Chertok et al. examined the effect of GDM on colostrum fatty acid composition. Analyses
of the fatty acid composition revealed significantly higher concentrations of four essential ω-6
polyunsaturated fatty acids (γ-linolenic, eicosatrienoic, arachidonic, and docosatetraenoic) in the
colostrum of GDM women, as compared to non-GDM women [29].
3.1.8. Electrolytes
Sodium was evaluated in two studies in colostrum, and both showed an increase of sodium
concentrations in correlation to GDM; moreover Galipau et al. found an increase in relation to insulin
use [15,30]. Potassium, phosphorus and calcium were analyzed by Kaushik et al. in the colostrum and
no differences were found [15].
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3.1.9. Vitamin E
GDM was not associated with changes in α-tocopherol concentration in the colostrum.
No correlation was found between the concentration of α-tocopherol in the serum and in the colostrum
for control and diabetic groups [31].
3.1.10. MicroRNA
A recent study evaluated the microRNAs levels (let-7a, miRNA-30B and miRNA-378) in HM, all
of which are known to participate in adipogenesis. Data showed a significant difference in let-7a and
miRNA-378 among the normal group and the GDM group. However, these differences disappeared
by controlling maternal pre-pregnancy BMI, because pre-pregnancy BMI was a confounder that was
correlated to gestational metabolic complications [32].
3.1.11. Metabolome
Wen et al. determined the human milk metabolome profile of GDM women over the first month
of lactation. A total of 187 metabolites were identified in the breast milk, including 4 alkanes, 17 amino
acid derivatives, 21 amino acids, 22 saturated fatty acids, 29 unsaturated fatty acids, 8 TCA cycle
intermediates, 3 cofactors or vitamins, 3 keto acids and derivatives, 1 glycolytic intermediate, 43 organic
acids, and 36 organic compounds. The metabolome composition and differences among the colostrum,
transition milk, and mature milk from GDM mothers shared many similarities with those from normal
pregnancies. However, there were 28 metabolites that were found to be significantly different between
women with normal pregnancies and women with GDM pregnancies in the colostrum, transition milk,
and mature milk samples [33].
3.2. Insulin-Dependent Diabetes Mellitus—IDDM
We found eight studies that focused on IDDM and all were published before the 21st century.
These articles evaluated the HM of diabetic women with diagnosis and exordium before the pregnancy,
with different durations of the pathology and different controls of the therapies. Four studies were
conducted based on the same protocol.
The results are summarized and reported in Tables 3 and 4.
Table 3. Materials and Methods of the different studies included in the survey regarding
insulin-dependent diabetes mellitus (IDDM) and HM.
Study
Metabolic
Control in
Pregnancy
Sample Time GestationalAge
Parameters
Analyzed
Sample Size
IDDM vs. Control
Women
[34] Moderatelycontrolled
24 h pool of mature
milk: 16–90 days Term
Total nitrogen,
lactose,
fat,
trace minerals,
lactoferrin,
sIgA,
glucose,
sodium.
5 vs. 42
[35] Poorlycontrolled 3, 4, 5, 6, 7 days Term
Lipids,
glucose,
lactose,
citrate,
sodium,
potassium,
chloride,
calcium,
magnesium,
total protein
1 vs. 13
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Table 3. Cont.
Study
Metabolic
Control in
Pregnancy
Sample Time GestationalAge
Parameters
Analyzed
Sample Size
IDDM vs. Control
Women
[36]
Tightly
controlled with
continuous
subcutaneous
insulin infusion
0, 3, 5, 7, 9, 10, 12,
15, 17, 21, 25, 29, 35
days
Term
Triglycerides,
lactose,
protein,
cholesterol,
glucose,
myoinositol,
fatty acid
6 vs. 5
[37] Tightlycontrolled
2, 3, 7, 14, 42, 84
days
Term
Preterm Prolactin
33 vs. 33 and 11
healthy reference
women
[38] Tightlycontrolled 3, 7, 14, 42, 84 days
Term
Preterm
Total lipid,
medium-chain fatty
acids,
saturated and
monounsaturated
long-chain fatty acid,
long chain
polyunsaturated
fatty acid
33 vs. 33 and 11
healthy reference
women
[39] Tightlycontrolled 7, 14, 42, 84 days
Term
Preterm Vitamin E
33 vs. 33 and 11
healthy reference
women
[40] Not indicated 8–10 days TermPreterm
Lactose,
citrate and glucose 6 vs. 38
[41] Tightlycontrolled
2, 3, 7, 14, 42, 84
days
Term
Preterm
Lactose,
total nitrogen,
conductivity,
osmolality
33 vs. 33 and 11
healthy reference
women
Table 4. Results of the different studies included in the survey regarding IDDM and HM.
Components Effects Reference
Total protein content No differences Col/Trans/mat: [34–36]
Lactoferrin No differences Mat: [34]
Glucose No differencesIncrease
Col/Trans/Mat: [36]
Mat: [34]
Lactose No differences Col/Trans/Mat: [34–36]
Myoinositol No differences Col/Trans/Mat: [36]
Total lipid content No differencesDecrease
Col/Trans/Mat: [34,36,38]
Col: [35]
Cholesterols No differencesDecrease
Col/Trans/Mat: [36]
Col/Trans/Mat: [36]
Triglycerides No differences Col: [36]
Fatty Acid Profile No differences Col/Trans/Mat: [36]
medium-chain fatty acid Decrease Col: [34]
No differences Col/Trans/Mat: [38]
polyunsaturated fatty acids Increase Col: [35]
Decrease Col/Trans/Mat: [38]
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Table 4. Cont.
Components Effects Reference
oleic acid Increase Col: [35]
Potassium, magnesium and
calcium No differences Col/Mat: [34,35]
Sodium No differencesIncrease
Col: [35]
Mat: [34]
Phosphorus, zinc, copper, iron No differences Mat: [34]
Chlorite and citrate No differences Col: [35]
Vitamin E No differences Col/Trans/Mat: [39]
3.2.1. Proteins
Three studies did not find a difference in concentrations in total protein content between groups,
although several differences were found in the protocol, as shown in Table 3 [34–36].
Only one study evaluated the lactoferrin and secretory IgA and no differences were found between
IDDM mothers and healthy mothers [34].
Another study investigated prolactin levels and found that, in the first postnatal week, milk
immunoreactive prolactin concentrations were lower for women with IDDM than for the control
group [37]. The significantly lower milk prolactin concentration could be related to elevated serum
glucose. High postprandial capillary glucose explained much of the variance in HM prolactin
measurements for IDDM mothers. The good glycemic control during pregnancy and early postpartum
period was associated with higher perinatal milk prolactin values. Moreover, the inverse relationship
between lactose and milk prolactin, which was significant at day 2 postpartum for reference women,
was delayed until day 14 postpartum for women with IDDM. These data reflect the delay in lactogenesis
and in establishment of lactation experience by IDDM mothers [37].
3.2.2. Lipids
Lipids are the nutrients more extensively studied in the relationship between IDDM and HM
composition: we found four different studies on this topic. The results are quite discordant: three
found no changes in total fat, but the data from Bitman et al. had a mean fat content 1.5 times lower in
IDDM [34–37].
The cholesterol level was tested in two studies, with opposite results: one observed five times
lower concentration, while the other observed no differences [35,36].
The triglycerides were evaluated in one study and no differences were found [36].
Fatty acid profile was analyzed in three different studies [35–37]. Van Beusekom et al. did
not find abnormalities in total fatty acid composition [36]. Bitman et al. demonstrated a decreased
medium-chain fatty acid, suggesting impairment of fatty acid synthesis in the mammary gland, and an
increased oleic acid and high concentrations of polyunsaturated fatty acids, suggesting increased chain
elongation [35]. Ferris et al. reported that medium-chain fatty acids in the group with IDDM were
similar to or greater than those of the control and reference groups at all times, and were within normal
reported ranges. In addition, HM long-chain polyunsaturated fatty acids were lower in women with
IDDM from 14 to 84 days postpartum [38].
3.2.3. Carbohydrates
Three studies evaluated the carbohydrate levels, per se, such as the macronutrients of HM [34–36].
The data agree in terms of lactose levels and no differences were found [34–36]. Results are discordant
for the glucose levels: Butte et al. observed that milk glucose was 2.3 times higher in IDDM mothers,
whereas Van Beusekom et al. did not find differences [34,36].
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In the end, one study analyzed the myoinositol levels and no differences were found [36].
3.2.4. Electrolytes
There were no differences in HM levels of potassium, calcium, magnesium between groups in two
different studies. The results of these studies are discordant regarding sodium: Butte et al. reported
that sodium was 1.2 times higher, but Bitman et al. did not find differences [34,35].
Moreover, no differences were found between groups for phosphorus, zinc, copper, iron [34]
concentrations in one study, and chlorite and citrate levels in another study [35].
3.2.5. Vitamins
Only one vitamin (i.e., alpha tocopherol) was analyzed in one study in IDDM HM. Tocopherol
decreased by 50% in all groups between 7–14 days postpartum [39], with no difference between groups.
3.2.6. Markers of Lactogenesis
Neubauer et al. and Arthur et al. evaluated the markers for the onset of milk secretion [40,41].
Arthur et al. reported that the peak in milk lactose occurred significantly later for women with
IDDM, suggesting that lactation was delayed. Concentrations of lactose, citrate and glucose increase
significantly in milk of IDDM between day 2 and 3. The plateau was reached for all metabolites on
day 4 [37]. These data confirm the results by Neubauer et al., finding a significantly lower lactose
and higher total nitrogen in the colostrum. Milk lactose increased significantly over time to 42 days
postpartum. Breast milk lactose was inversely correlated with breast milk conductivity at 3 days
postpartum. Total nitrogen was also inversely correlated with milk lactose for women with IDDM.
Conductivity and osmolality did not differ among the three group [40].
4. Discussion
Diabetes is a frequent pathology during pregnancy that potentially determines several
complications and is a significant risk factor for newborn morbidity [6,42]. The impact of maternal
metabolic abnormalities on early postnatal nutrition and infant metabolic curves is of considerable
interest, because the offspring of women, both with preexistent diabetes or GDM, are at increased
long-term risk for type 2 diabetes, although epidemiologic evidence has also shown a long-term
protective effect of breastfeeding against obesity and type 2 diabetes in offspring [1–3,43]. Based on
this strong correlation between maternal and neonatal morbidity, it is important to know the effects of
this condition on the composition of HM, especially in relation to the benefits mediated by the HM
for newborns [1–3]. In the absence of any clear conclusion about this topic, clinical practice should
continue to promote and support breastfeeding, as indicated in recognized international guidelines [1],
also for GDM women.
Until now, few studies have been reported in the literature assessing the composition of the human
milk of diabetic mothers. The main observation is that GDM and IDDM can alter the composition
of HM milk. The effect on HM is present not only in the first day post-partum, but is continued
throughout all of the lactating phases. These studies hypothesize that the modification inducted by
GDM have a potential role that can be, not only detrimental but also protective for the babies. The data
on IDDM highlight that the modification of the composition is related to the control of the pathology.
However, we believe that these studies present some limitations:
(i) Several studies analyzed only one phase of milk and did not consider the variation at different
time points during lactation. In addition, the definition of the different phases of lactation are not
univocal, i.e., the time of sampling of colostrum ranges between 24 h and 7 days postpartum.
(ii) Some studies do not have a case/control protocol focused on GDM or IDDM, but rather, evaluate
the effect of preterm delivery; diabetes is considered in metanalysis as a risk factor.
(iii) Concomitant drug therapies are rarely considered and analyzed.
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(iv) The studies focused on IDDM are all published before 21st century, and four have the same
protocol study.
(v) No dedicated study focused on type 2 diabetes is present in literature.
5. Conclusions
The number of available studies on this topic is scarce and they evaluate the effects of diabetes on
a few specific milk biochemical markers with several and heterogeneous variables. Bearing in mind
the previous considerations, it is therefore difficult to quantify the real effect of this pathology on the
different components of HM, or on the health benefits mediated by mother’s milk for the child. Future
studies are needed to obtain a more comprehensive evaluation. Moreover, we believe that the protocols
should be assessed with case/control structure, specifically focused on preterm delivery and with a
match on gestational age (GA). It will also be important to analyze the effect of different diabetes drugs
on HM and their potential interaction on the different biological components. Finally, considering
the rising prevalence of type 2 diabetes in association with obesity, we believe it is important to plan
future studies to determine possible effects on human milk in this population. These future findings
are important to individualize and modify the maternal therapies and supplement the nutrition of the
preterm newborns.
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American Academy of Pediatrics AAP
Body mass index BMI
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